IMR Press / FBE / Volume 8 / Issue 1 / DOI: 10.2741/E760

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

SOCS2: physiological and pathological functions

Show Less
1 Molecular Disease Mechanisms Group, Life Sciences Research Unit, University of Luxembourg, 162A avenue de la Faïencerie, L-1511 Luxembourg, Luxembourg

*Author to whom correspondence should be addressed.

Academic Editor: Serge Haan

Front. Biosci. (Elite Ed) 2016, 8(1), 189–204; https://doi.org/10.2741/E760
Published: 1 January 2016
(This article belongs to the Special Issue Regulation of signalling in health and disease)
Abstract

Suppressors of cytokine signalling (SOCS) proteins are modulators of cytokine and growth factor signalling whose aberrant regulation has been linked to a variety of inflammatory and neoplastic diseases. SOCS proteins are able to act as substrate-recruiting component of E3-ubiquitin ligase complexes and target interacting proteins for degradation. At least some of the family members can also directly inhibit tyrosine kinases such as Janus Kinases (JAK). The most studied family members, CIS, SOCS1, SOCS2 and SOCS3 are important regulators of the JAK-STAT pathway. Here, we focus on SOCS2 and review its biological function as well as its implication in pathological processes. Furthermore, we take advantage of the known crystal structures of SOCS2 to discuss the potential effects of a selection of SOCS2 mutations that were identified in tumour tissues.

Keywords
SOCS2
GH signalling
Cancer
CNS
Immune Disorders
Review
Share
Back to top